Substance / Medication

Retapamulin

Overview

Active Ingredient

retapamulin

RxNorm CUI

642274

Indications

2 Staphylococcus aureus Streptococcus pyogenes [see Clinical Studies (14)] ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cmin total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to(methicillin-susceptible isolates only) or. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ALTABAX and other antibacterial drugs, ALTABAX shou

Labeler: Rebel Distributors Corp.Updated: 2010-09-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Impetigo

Bacterial infectious disease

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

NCT00555061Phase 4Completed60 enrolled

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268Phase 4Completed38 enrolled

Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

NCT02775617Phase 4Completed1291 enrolled

Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

NCT07428915Completed15 enrolled

View all 4 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.

Gropper Savion, Albareda Nuria, Chelius Klaus et al. · Future Microbiol · 2014

PMID: 25340832Observational

A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus.

Tanus Tonny, Scangarella-Oman Nicole E, Dalessandro Marybeth et al. · Adv Skin Wound Care · 2014

PMID: 25396674Observational

The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study.

Tomayko John F, Li Gang, Breton John J et al. · Adv Skin Wound Care · 2013

PMID: 23426412Observational

Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.

Koning S, van der Wouden J C, Chosidow O et al. · Br J Dermatol · 2008

PMID: 18341664Observational

Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates.

Goldstein Ellie J C, Citron Diane M, Merriam C Vreni et al. · Antimicrob Agents Chemother · 2006

PMID: 16377717ObservationalFull text (PMC)

Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.

Kosowska-Shick Klaudia, Clark Catherine, Credito Kim et al. · Antimicrob Agents Chemother · 2006

PMID: 16436741ObservationalFull text (PMC)

Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Pankuch Glenn A, Lin Gengrong, Hoellman Dianne B et al. · Antimicrob Agents Chemother · 2006

PMID: 16641442ObservationalFull text (PMC)

Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.

Parish Lawrence Charles, Jorizzo Joseph Lucius, Breton John Jeffrey et al. · J Am Acad Dermatol · 2006

PMID: 17097398Observational

Allergic contact cermatitis to retapamulin ointment.

Schalock Peter C · Contact Dermatitis · 2009

PMID: 19706058Case Report

Retapamulin alleviates DSS-induced ulcerative colitis via direct AMPK activation and modulation of the gut microbiota-metabolite axis.

Yang Xin, Wang Zhi-Wei, Liu Zhen-Lin et al. · Int Immunopharmacol · 2026

PMID: 41242270Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Retapamulin (substance)
SNOMED CT: 427137002
UMLS CUI: C1703334
RxNorm CUI: 642274
Labeler: Rebel Distributors Corp.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.